RecruitingPhase 2Drug trialAllo HSCT for High Risk HemoglobinopathiesA single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.